Effects of a combined treatment with GPR30 agonist G-1 and herceptin on growth and gene expression of human breast cancer cell lines

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 372-379

  Lubig, Julia ^a   Lattrich, Claus ^a   Springwald, Anette ^a   Häring, Julia ^a   Schüler, Susanne ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Breast cancer; Combined treatment; G 1; Gene expression; GPR30; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; CYCLIN A2; CYCLIN D1; G 1; G PROTEIN COUPLED RECEPTOR 30; MESSENGER RNA; P21 ACTIVATED KINASE 1; PROTEIN C FOS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; GENES, FOS; HUMANS; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84861043226     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.666690     Document Type: Article

References (41)

1. Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, Zheng W. Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. Oncol Rep 2008;19(5):1347-1354.
2. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116(12):2856-2867.
3. Hayashida T, Jinno H, Sakata M, Takahashi M, Kitagawa Y. Current strategies of primary therapy for breast cancer. Nippon Rinsho 2010;68(6):1137-1142.
4. Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010;10(5):711-721.
5. Wren BG. The origin of breast cancer. Menopause 2007; 14(6):1060-1068. (Pubitemid 350098667)
6. Welboren WJ, Sweep FC, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009;16(4):1073-1089.
7. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M. G protein coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007;67(4):1859-1866. (Pubitemid 46383413)
8. Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor GPR30 with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 2008;73(9-10):870-873.
9. Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C. A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010;75(8-9):603-610.
10. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH. G protein-coupled receptor 30 localizes to the endoplasmatic reticulum and is not activated by estradiol. Endocrinology 2008;149(10):4846-4856.
11. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2(4):175-176.
12. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008;70:165-190. (Pubitemid 351738176)
13. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in themechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 2010;123(1):87-96.
14. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 2010;70(3):1184-1194.
15. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants oftumor progression. Clin Cancer Res 2006;12(21):6359-6366. (Pubitemid 44799705)
16. Tokuda Y, Suzuku Y, Saito Y,Umemura S.Therole of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 2009;16(4):295-300.
17. Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A, Kallioniemi A. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 2004;23(4):1010-1013. (Pubitemid 38250948)
18. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009;308(1-2):32-38.
19. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009;28(5):523-532.
20. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010;70(14):6036-6046.
21. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. Gprotein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Comun 2006; 346(3):904-910.
22. Revankar CM, Cimino DF, Sklar LA, Arteburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science 2005;307(5715):1625-1630. (Pubitemid 40354745)
23. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to aGprotein in human breast cancer cells. Endocrinology 2005;146(2):624-632. (Pubitemid 40129818)
24. Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 2010;57(2):101-107.
25. Filardo E, Quinn J, Pang Y, Graber C, Shaw S, Dong J, Thomas P. Activation of the novel estrogen receptor G proteincoupled receptor 30 at the plasma membrane. Endocrinology 2007;48(7):3236-3245. (Pubitemid 46997004)
26. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006;20(9):1996-2009. (Pubitemid 44286700)
27. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Nuclear and extranuclear pathway inputs in the reulation of global gene expression by estrogen receptors. Mol Endocrinol 2008;22(9):2116-2127.
28. Ahola TM, Manninen T, Alkio N, Ylikomi T. G proteincoupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002; 143(9):3376-3384. (Pubitemid 34925712)
29. Teng J, Wang ZY, Prossnitz ER, Bjorling DE. The G proteincoupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 2008;149(8):4024-4034.
30. ChanQK, LamHM,Ng CF, Lee AY, Chan ES,NgHK,Ho SM, Lau KM. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of ERK1/2, c-jun/c-fos- dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010;17(9):1511-1523.
31. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+transfer in the control of apoptosis. Oncogene 2008;27(50):6407-6018.
32. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogeninduced activation of Erk-1 and Erk-2 requires the G proteincoupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HBEGF. Mol Endocrinol 2000;14(10):1649-1660.
33. Vivacqua A, Lappano R, DeMarco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Ando S, Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha positive cancer cells. Mol Endocrinol 2009;23(11):1815-1826.
34. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.Chin Med J (Engl) 2009;122(22):2763-2769.
35. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, SemczukA, Roessner A, Costa SD, Kalinski T. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011;128(2):457-466.
36. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005;41(16): 2449-2461. (Pubitemid 41540622)
37. Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells.Cancer Res 1988;48(4):802-805. (Pubitemid 18061866)
38. Basu A, Rowan BG. Genes related to estrogen action in reproduction and breast cancer. Front Biosci 2005;10:2346-2372. (Pubitemid 40905305)
39. Liu J, Liu YG, Huang R, Yao C, Li S, Yang W, Yang D, Huang RP. Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 2007;4(6):377-385.
40. Ronski K, SandersM, Burleson JA,Moyo V, Benn P, Fang M. Early growth response gene 1 is deleted in estrogen receptor-negative human breast carcinoma. Cancer 2005;104(5):925-930. (Pubitemid 41170218)
41. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM,Mercola D, Adamson ED. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumour formation. Int J Cancer 1997;72(1):102-109. (Pubitemid 27314646)